Olmesartan detailed information: Difference between revisions

Jump to navigation Jump to search
m (Protected "Olmesartan detailed information": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
Line 21: Line 21:
{{CMG}}
{{CMG}}
__NOTOC__
__NOTOC__
{{Editor Join}}
 


==[[Olmesartan (patient information)|For patient information, click here]]==
==[[Olmesartan (patient information)|For patient information, click here]]==

Revision as of 14:29, 20 August 2012

Olmesartan detailed information
Clinical data
Pregnancy
category
  • C (D if used in second or third trimester)
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
BioavailabilityRapid and complete absorption
MetabolismHepatic (cannot be removed by hemodialysis)
Elimination half-life13 hours
ExcretionPrimarily fecal, 35%-50% in urine
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC29H30N6O6
Molar mass558.585 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


For patient information, click here

Overview

Olmesartan (Benicar®,Olmetec®) belongs to the class of medicines called angiotensin II receptor antagonists to treat high blood pressure. It is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc. and Forest Laboratories. Olmesartan works by blocking the binding of angiotension II to the AT1 receptors in vascular muscle; it is therefore independent of angiotension II synthesis pathways, unlike ACE inhibitors. By blocking binding rather than synthesis of angiotension II, olmesartan inhibits the negative regulatory feedback on renin secretion. As a result of this blockage, olmesartan restricts vasoconstriction and the secretion of aldosterone. This lowers blood pressure by producing vasodilation, and decreasing peripheral resistance.

Administration

Olmesartan is available in 5, 20, and 40 mg tablets. A normal dose for an adult (including the elderly and mild renal or hepatic impairment) is 20 mg/day in one dosage. This may be increased after two weeks to 40 mg/day if further blood pressure reduction is needed.

Side effects

Side effects include:

References

Hodgson, Barbara B., and Kizior, Robert J. Saunders Nursing Drug Handbook 2006. St. Louis, MO: Elsevier, Saunders, 2006.

External links

Template:Angiotensin II receptor antagonists

de:Olmesartan hu:Olmesartan


Template:WikiDoc Sources